share_log

Barclays Maintains Equal-Weight on Revance Therapeutics, Lowers Price Target to $3

Benzinga ·  Dec 23 20:43  · Ratings

Barclays analyst Balaji Prasad maintains Revance Therapeutics (NASDAQ:RVNC) with a Equal-Weight and lowers the price target from $7 to $3.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment